Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Gilberto Lopes et al.|The Lancet|2019Cited by 3.3k
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Robert I. Haddad et al.|The Lancet Oncology|2015Cited by 394
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Dae Ho Lee et al.|Journal of Clinical Oncology|2024Cited by 137
Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)Vincent Launay‐Vacher, Ben Sprangers, Matti Aapro et al.|Annals of Oncology|2015Cited by 79
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Naiyer A. Rizvi et al.|Journal of Thoracic Oncology|2022Cited by 72